CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases

M. Paganuzzi, M. Onetto, P. Marroni, D. Barone, M. Conio, H. Aste, V. Pugliese

Research output: Contribution to journalArticlepeer-review

Abstract

Serum concentrations of the CA 19-9 and CA 50 antigens were determined in 129 patients with malignant and benign biliary and pancreatic diseasse. Values for the two markers were highly correlated (P <0.001). The concentrations of CA 19-9 and CA 50 were positive in 84.6% and 80.7% of patients with pancreatic cancer, respectively. The overall specificity of CA 19-9 (92.4%) was slightly higher than that of CA 50 (88.5%). The sensitivity of CA 50 (91.3%) was greater than that of CA 19-9 (73.9%) in patients with diseases of the biliary tract. Elevated concentrations of CA 19-9 (12.9%) and CA 50 (38.2%) were also found in a number of cases with benign disease, especially in patients with obstructive jaundice. These data suggest that both CA 19-9 and CA 50 can be useful markers of pancreatic cancer in nonjaundiced patients. The joint use of the two markers does not yield a better diagnostic resolution than the use of either one alone.

Original languageEnglish
Pages (from-to)2100-2108
Number of pages9
JournalCancer
Volume61
Issue number10
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases'. Together they form a unique fingerprint.

Cite this